BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai HY, Yang D, Qiao J, Yang JT, Wang ZJ, Wu MN, Qi JS, Hölscher C. A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease. J Alzheimers Dis 2021. [PMID: 34366339 DOI: 10.3233/JAD-210256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao W, Hu X, Yu K, Cai H, Wang Z, Wang L, Wu M. Selective orexin 1 receptor antagonist SB-334867 aggravated cognitive dysfunction in 3xTg-AD mice. Behavioural Brain Research 2023;438:114171. [DOI: 10.1016/j.bbr.2022.114171] [Reference Citation Analysis]
2 Li Y, Yu K, Cui Y, Wang Z, Cai H, Cao J, Wu M. Orexin-A aggravates cognitive deficits in 3xTg-AD mice by exacerbating synaptic plasticity impairment and affecting amyloid β metabolism. Neurobiology of Aging 2023. [DOI: 10.1016/j.neurobiolaging.2023.01.008] [Reference Citation Analysis]
3 Du H, Meng X, Yao Y, Xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. Front Endocrinol (Lausanne) 2022;13:1033479. [PMID: 36465634 DOI: 10.3389/fendo.2022.1033479] [Reference Citation Analysis]
4 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
5 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106550] [Reference Citation Analysis]
6 Cai H, Qiao J, Chen S, Yang J, Hölscher C, Wang Z, Qi J, Wu M. MCU knockdown in hippocampal neurons improves memory performance of an Alzheimer's disease mouse model. Acta Biochim Biophys Sin (Shanghai) 2022;54:1528-39. [PMID: 36239352 DOI: 10.3724/abbs.2022138] [Reference Citation Analysis]
7 Tao P, Xu W, Gu S, Shi H, Wang Q, Xu Y. Traditional Chinese medicine promotes the control and treatment of dementia. Front Pharmacol 2022;13:1015966. [DOI: 10.3389/fphar.2022.1015966] [Reference Citation Analysis]
8 Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 2022;16:970925. [DOI: 10.3389/fnins.2022.970925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Diz-chaves Y, Mastoor Z, Spuch C, González-matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. IJMS 2022;23:9583. [DOI: 10.3390/ijms23179583] [Reference Citation Analysis]
10 Hölscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Front Synaptic Neurosci 2022;14:955258. [DOI: 10.3389/fnsyn.2022.955258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dong W, Cui M, Hu W, Zeng Q, Wang Y, Zhang W, Huang Y. Genetic and Molecular Evaluation of SQSTM1/p62 on the Neuropathologies of Alzheimer’s Disease. Front Aging Neurosci 2022;14:829232. [DOI: 10.3389/fnagi.2022.829232] [Reference Citation Analysis]
12 Kabel AM, Arab HH, Atef A, Estfanous RS. Omarigliptin/galangin combination mitigates lipopolysaccharide-induced neuroinflammation in rats: Involvement of glucagon-like peptide-1, toll-like receptor-4, apoptosis and Akt/GSK-3β signaling. Life Sci 2022;295:120396. [PMID: 35157909 DOI: 10.1016/j.lfs.2022.120396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]